FDA mulls upping risk classification of vaginal mesh as lawsuits mount up for big mesh makers
This article was originally published in Clinica
Transvaginal meshes to treat pelvic organ prolapse may soon be classified as "high-risk" devices requiring premarket approval, pending the outcome of a two-day US FDA panel meeting to discuss the safety and efficacy of the products. These meshes, made by the likes of Johnson & Johnson and CR Bard, were previously regulated under the less-stringent 510(k) procedures. However, growing concern over serious complications arising in patients implanted with the devices have prompted calls for stricter regulation.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.